CLINICAL TRIALS PROFILE FOR NILOTINIB HYDROCHLORIDE MONOHYDRATE
✉ Email this page to a colleague
All Clinical Trials for nilotinib hydrochloride monohydrate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04205903 ↗ | Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer | Recruiting | National Cancer Institute (NCI) | Phase 1 | 2020-12-11 | This phase Ib/II trial studies the side effects and best dose of nilotinib in preventing paclitaxel-induced peripheral neuropathy in stage I-III breast cancer patients who are receiving paclitaxel therapy. Chemotherapy is the usual or ?standard? treatment for breast cancer. It kills cancer cells and lowers the chance that the cancer will come back. Sometimes, this treatment can cause numbness and tingling, especially in the hands and feet. This is called chemotherapy-induced peripheral neuropathy. This study aims to test the safety and effectiveness, both good and bad, of taking nilotinib in preventing chemotherapy-induced peripheral neuropathy. |
| NCT04205903 ↗ | Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer | Recruiting | Ohio State University Comprehensive Cancer Center | Phase 1 | 2020-12-11 | This phase Ib/II trial studies the side effects and best dose of nilotinib in preventing paclitaxel-induced peripheral neuropathy in stage I-III breast cancer patients who are receiving paclitaxel therapy. Chemotherapy is the usual or ?standard? treatment for breast cancer. It kills cancer cells and lowers the chance that the cancer will come back. Sometimes, this treatment can cause numbness and tingling, especially in the hands and feet. This is called chemotherapy-induced peripheral neuropathy. This study aims to test the safety and effectiveness, both good and bad, of taking nilotinib in preventing chemotherapy-induced peripheral neuropathy. |
| NCT05554341 ↗ | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial | Not yet recruiting | National Cancer Institute (NCI) | Phase 2 | 2022-12-09 | This phase II trial evaluates nilotinib with paclitaxel for the treatment of patients with solid cancers that are growing, spreading, or getting worse (progressive) and that have previously been treated with taxane therapies. Nilotinib is in a class of medications called kinase inhibitors. It works by binding to and blocking the action of a protein called ABL, which signals cancer cells to multiply. This helps slow or stop the proliferation of cancer cells. Paclitaxel is a drug that blocks cell growth by stopping cell division and it may kill cancer cells. Giving nilotinib with paclitaxel may be effective at treating patients with progressive solid cancers that have previously been treated with taxane therapies. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for nilotinib hydrochloride monohydrate
Condition Name
| Condition Name for nilotinib hydrochloride monohydrate | |
| Intervention | Trials |
| Anatomic Stage IIB Breast Cancer AJCC v8 | 1 |
| Prognostic Stage IIA Breast Cancer AJCC v8 | 1 |
| Anatomic Stage III Breast Cancer AJCC v8 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for nilotinib hydrochloride monohydrate
Trials by Country
Clinical Trial Progress for nilotinib hydrochloride monohydrate
Clinical Trial Phase
Clinical Trial Sponsors for nilotinib hydrochloride monohydrate
Sponsor Name
